A. Kalsekar

发表

Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.

Jinlin Song, J. Signorovitch, E. Swallow, 2016, Journal of comparative effectiveness research.

Using the Fib-4 Score to Monitor Morbidity and Mortality Risk in Chronic Hepatitis C Patients

J. Mccombs, S. Saab, T. Matsuda, 2016 .

Epidemiology, treatment and health economics of Hepatitis C in Japan (Review)

I. Kamae, P. McEwan, M. Kobayashi, 2014 .

Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies

B. Jones, J. Gordon, P. McEwan, 2017, The European Journal of Health Economics.

G. L’italien, K. Chayama, J. Toyota, 2014, Value in health regional issues.

Association of insomnia severity and comorbid medical and psychiatric disorders in a health plan-based sample: Insomnia severity and comorbidities.

J. Walsh, C. Morin, K. Sarsour, 2010, Sleep medicine.

Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.

E. Wu, C. Behrer, D. Macaulay, 2015, Journal of managed care & specialty pharmacy.

Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.

T. Le, E. Wu, D. Macaulay, 2015, Clinical therapeutics.

Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis

K. Kelly, M. Bonafede, A. Kalsekar, 2011, BMC endocrine disorders.

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

P. McEwan, T. Ward, Yong Yuan, 2017, Cost Effectiveness and Resource Allocation.

The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK

J. Gordon, P. McEwan, T. Ward, 2015, European journal of gastroenterology & hepatology.

The Implications of Acute Rejection for Allograft Survival in Contemporary U.S. Kidney Transplantation

G. L’italien, M. Schnitzler, D. Axelrod, 2012, Transplantation.

The Implications of Acute Rejection and Reduced Allograft Function on Health Care Expenditures in Contemporary US Kidney Transplantation

G. L’italien, M. Schnitzler, D. Axelrod, 2012, Transplantation.

Patient-Reported Outcomes in Insomnia: Development of a Conceptual Framework and Endpoint Model

Daniel J Buysse, T. Roth, K. Lichstein, 2013, Behavioral sleep medicine.

Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.

Junlong Li, K. Betts, Yan Song, 2015, Journal of comparative effectiveness research.

Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections

P. McEwan, D. Sugrue, Yong Yuan, 2015, PloS one.

Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors

J. Weiss, A. Kalsekar, K. Amiri, 2022, JTO clinical and research reports.

An Epidemiological Model to Estimate the Prevalence of Diffuse Large B-Cell Lymphoma in the United States.

M. Hutchings, D. Chihara, K. Johnston, 2022, Clinical lymphoma, myeloma & leukemia.

Estimating the cost‐effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b

I. Kamae, P. McEwan, M. Kobayashi, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Subtypes of Sleep Disturbance: Associations Among Symptoms, Comorbidities, Treatment, and Medical Costs

K. Sarsour, K. Foley, A. Kalsekar, 2010, Behavioral sleep medicine.

Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease

B. Jones, J. Gordon, P. McEwan, 2016, Clinical Drug Investigation.

Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b.

I. Kamae, S. Berry, K. Broglio, 2014, Value in health regional issues.

Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma

Sally D. Miller, K. Sail, A. Kalsekar, 2022, Journal of comparative effectiveness research.

An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK

K. Boye, W. Valentine, J. Arellano, 2009, Diabetic medicine : a journal of the British Diabetic Association.

Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis

Lizheng Shi, V. Fonseca, Jinan Liu, 2010, Health and quality of life outcomes.

A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients

B. Kasiske, G. L’italien, A. Levy, 2014, Current Medical Research and Opinion.

Projecting long-term graft and patient survival after transplantation.

Andrew H Briggs, Adrian R Levy, G. L’italien, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C

P. McEwan, T. Ward, Yong Yuan, 2015, PloS one.

Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices

Lizheng Shi, V. Fonseca, Jinan Liu, 2012, PharmacoEconomics.

Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System.

J. Hay, T. Cheetham, L. Nyberg, 2015, Journal of managed care & specialty pharmacy.

A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.

R. Lewis, E. Daar, B. Spellberg, 2015, Journal of comparative effectiveness research.

Health state utilities associated with attributes of treatments for hepatitis C

D. Feeny, L. Matza, J. Dillon, 2014, The European Journal of Health Economics.

The Impact of Obesity on Adverse Cardiovascular Outcomes in the General Population and in patients with Type 2 Diabetes

K. Boye, G. Goodall, J. Palmer, 2009 .

The association between insomnia severity and healthcare and productivity costs in a health plan sample.

R. Swindle, K. Sarsour, K. Foley, 2011, Sleep.

Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder

E. Dunayevich, J. Mauskopf, G. Simon, 2009, Depression and anxiety.

A clinician’s guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective

M. Thursz, J. Gordon, P. McEwan, 2017, European journal of gastroenterology & hepatology.

Sleep Problems, Comorbid Mental Disorders, and Role Functioning in the National Comorbidity Survey Replication

R. Kessler, S. Jaeger, R. Jin, 2006, Biological Psychiatry.

Use of 12-Month Renal Function and Baseline Clinical Factors to Predict Long-Term Graft Survival: Application to BENEFIT and BENEFIT-EXT Trials

G. L’italien, M. Schnitzler, D. Axelrod, 2012, Transplantation.

Influence of renal function on long-term graft survival and patient survival in renal transplant recipients

J. Smith-Palmer, W. Valentine, A. Kalsekar, 2014, Current medical research and opinion.

Beneficial Effect of Belatacept on Health-Related Quality of Life and Perceived Side Effects: Results From the BENEFIT and BENEFIT-EXT Trials

F. Dobbels, Schiffon Wong, A. Kalsekar, 2014, Transplantation.

Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.

Jinlin Song, Caroline Kelley, Jinlin Song, 2016, Clinical therapeutics.

Brief review Influence of renal function on long-term graft survival and patient survival in renal transplant recipients

J. Smith-Palmer, W. Valentine, A. Kalsekar, 2014 .

PIN11 The Impact of Directly Observed Therapy (DOT) in Patients with Tuberculosis

L. Kleinman, A. Kalsekar, R. Sallum, 2011 .

Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors

J. Weiss, A. Kalsekar, K. Amiri, 2022, JTO clinical and research reports.

Nonrestorative sleep.

Daniel J. Taylor, Kristen C Stone, K. Lichstein, 2008, Sleep medicine reviews.

Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

T. Phillips, P. Lugtenburg, C. Thieblemont, 2022, Blood.

Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes.

W. Valentine, R. Pollock, D. Bruhn, 2011, Current diabetes reviews.

Daclatasvir +Asunaprevir Versus Sofosbuvir/Ledipasvir for The Treatment of Chronic Hepatitis C Genotype 1 In Japanese Patients: A Matching-Adjusted Indirect Comparison.

J. Signorovitch, E. Swallow, L. Ristovska, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Use of 12-Month Renal Function and Baseline Clinical Factors to Predict Long-Term Graft Survival: Application to BENEFIT and BENEFIT-EXT Trials

G. L’italien, M. Schnitzler, D. Axelrod, 2012, Transplantation.

The Implications of Acute Rejection and Reduced Allograft Function on Health Care Expenditures in Contemporary US Kidney Transplantation

G. L’italien, M. Schnitzler, D. Axelrod, 2012, Transplantation.

Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.

Junlong Li, K. Betts, Yan Song, 2015, Journal of comparative effectiveness research.

Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder

E. Dunayevich, J. Mauskopf, G. Simon, 2009, Depression and anxiety.

Influence of renal function on long-term graft survival and patient survival in renal transplant recipients

J. Smith-Palmer, A. Kalsekar, William J. Valentine, 2014, Current medical research and opinion.

An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK

J. Arellano, A. Kalsekar, C. Pratoomsoot, 2009, Diabetic medicine : a journal of the British Diabetic Association.

A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures

K. Kelly, M. Bonafede, A. Kalsekar, 2010, Patient preference and adherence.

Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies

D. Mytelka, L. Garrison, A. Chawla, 2014, Pharmacoepidemiology and Drug Safety.

Projecting long-term graft and patient survival after transplantation.

G. L’italien, A. Levy, M. Schnitzler, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.